Ceritinib (LDK378)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

ALK-positive NSCLCAnaplastic Large Cell LymphomaGlioblastomaInflammatory Myofibroblastic TumorTumors With Aberrations in ALK

Phase 1

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Active, not recruitingNCT02393625

Novartis PharmaceuticalsALK-positive NSCLC

Start: 2015-05-27End: 2027-04-09Updated: 2026-09-17

Phase 2

Ceritinib Rare Indications Study in ALK+ Tumors

TerminatedNCT02465528

Novartis PharmaceuticalsAnaplastic Large Cell Lymphoma, Glioblastoma, Inflammatory Myofibroblastic Tumor +1

Start: 2016-05-06End: 2018-08-20Updated: 2019-12-27

Related Papers

An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).

Journal of Clinical Oncology2020-05-203 citations

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2017-05-2037 citations